The Commerce Department's 'Casey' initiative is evaluating unreleased models from major labs like OpenAI and Google. This silent approval process could slow public releases, give government exclusive access, and create hurdles for new entrants, effectively forming a regulatory moat that benefits established players.

The traditional government model of setting a regulation and waiting years to assess it is obsolete for AI. A new approach is needed: a dynamic board of government, industry, and academic leaders collaborating to make and update rules in real-time.

The White House's proposed legislative framework explicitly recommends against creating a new, overarching federal body to regulate AI. Instead, it advocates for empowering existing agencies with subject-matter expertise (e.g., in finance or healthcare) to develop and enforce AI rules within their own domains, suggesting a decentralized approach to governance.

The 'FDA for AI' analogy is flawed because the FDA's rigid, one-drug-one-disease model is ill-suited for a general-purpose technology. This structure struggles with modern personalized medicine, and a similar top-down regime for AI could embed faulty assumptions, stifling innovation and adaptability for a rapidly evolving field.

Leading AI companies allegedly stoke fears of existential risk not for safety, but as a deliberate strategy to achieve regulatory capture. By promoting scary narratives, they advocate for complex pre-approval systems that would create insurmountable barriers for new startups, cementing their own market dominance.

Silicon Valley's economic engine is "permissionless innovation"—the freedom to build without prior government approval. Proposed AI regulations requiring pre-approval for new models would dismantle this foundation, favoring large incumbents with lobbying power and stifling the startup ecosystem.

An FDA-style regulatory model would force AI companies to make a quantitative safety case for their models before deployment. This shifts the burden of proof from regulators to creators, creating powerful financial incentives for labs to invest heavily in safety research, much like pharmaceutical companies invest in clinical trials.

Contrary to the belief that compliance stifles progress, regulations provide the necessary boundaries for AI to develop safely and consistently. These 'ground rules' don't curb innovation; they create a stable 'playing field' that prevents harmful outcomes and enables sustainable, trustworthy growth.

Beyond its stated ideals, the White House's AI framework has a key political aim: to preempt individual states from creating a patchwork of AI laws. This reflects a desire to centralize control over AI regulation, aligning with the tech industry's preference for a single federal standard.